VB-008 in the Corneal Repair Landscape

TL;DR

• Corneal repair options map to layers: epithelium, stroma, endothelium, or full-thickness.

• VB-008 targets the epithelium with an autologous oral mucosal cell-sheet, distinct from donor grafts or limbal-cell approaches.

• Early clinical work focuses on procedure feasibility and safety in LSCD.

• The value test: consistent manufacturing, reliable surgical handling, and clear, conservative reporting.

To understand why Visionary BioMed picked the corneal epithelium as its starting point, it helps to look at the map of corneal repair. The cornea has distinct layers—epithelium on the surface, the thick stroma beneath, and the endothelium at the back. Technologies are often organized by which layer they address. VBM’s materials include layer-based comparison tables to orient you: epithelium, stroma, endothelium, and full-thickness solutions.

Full-thickness approaches historically include donor corneal transplantation and certain artificial cornea devices. These can be vision-saving in the right settings, but they depend on donors, long surgical times, and the complexity of transplant management. Endothelial techniques address the pumping layer at the back of the cornea; for the purposes of LSCD (a surface-renewal problem), they’re the wrong layer. That leaves the epithelium, where the day-to-day renewal should come from limbal stem cells at the edge.

In the epithelial space, you’ll find at least three families: (1) procedures that relocate or expand limbal cells, (2) donor epithelial tissues prepared on amniotic or other carriers, and (3) autologous oral mucosal epithelium engineered as a sheet. VBM’s own method is in the third category. The company’s decks explicitly call out “autologous oral mucosal epithelial cells” cultured ex vivo and transferred as a sheet for corneal surface repair.

It’s worth noting that an epithelial cell-sheet therapy using limbal cells (Holoclar) has been approved in Europe. That doesn’t prove results for oral mucosa, but it does show that a living epithelial sheet can meet regulatory expectations when supported by data and manufacturing controls. Visionary BioMed’s materials list Holoclar as “on market,” placing it in context rather than as a direct head-to-head comparison.

So what’s distinct about VB-008? First, the source: the inner cheek offers an accessible, autologous epithelial reservoir that can be harvested without touching the eye. Second, the format: a cohesive sheet that surgeons can place directly on the cornea. Third, the release: methods that lift the sheet without enzymes, preserving surface integrity—backed by issued patents on supports for culture and cell-sheet detachment. In principle, that can make the operating step more controlled: pick up the sheet, position it, and let it seat on the corneal surface.

The care pathway envisioned by the company is clear: collect a tiny oral sample, culture and prepare the sheet, place it on the eye in a short procedure, and follow the patient. The lab phase typically runs ~21 days. From a clinician’s perspective, that’s a cadence you can plan around; from a patient’s perspective, it’s a defined wait tied to a personalized product made from their own cells.

None of this means VB-008 will be right for every ocular surface problem. LSCD is heterogeneous, and surgeons will continue to pick from a toolbox that includes donor tissue, limbal procedures, and, where appropriate, devices. The value test for VB-008 will be whether it can be manufactured consistently, handled reliably in surgery, and—over time—demonstrate a surface that behaves like a healthy epithelium in the right patients.

For investors and partners, watch for evidence that the company is doing the unglamorous work: documenting every step, validating equipment, qualifying sites, and publishing measured updates. The early Phase 1 experience in Taiwan is not about market claims; it’s about building a reproducible process and a responsible evidence base for an autologous epithelial sheet made from oral mucosa.

The broader picture is hopeful. If VB-008 proves out and the platform holds, it could open doors to epithelial repair in other tissues—something the company’s decks outline in concept (endometrium, skin, esophageal and respiratory epithelium, and more). Those are long roads, but they begin with one thing done well: restoring the corneal surface, one carefully engineered sheet at a time.

Disclosure: All product candidates are investigational and not approved for commercial use. Forward-looking statements involve risks and uncertainties.